349 related articles for article (PubMed ID: 32538743)
1. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-99a expression in oral squamous cell carcinoma.
Chen L; Hu J; Pan L; Yin X; Wang Q; Chen H
Cancer Biomark; 2018; 23(3):333-339. PubMed ID: 30223386
[TBL] [Abstract][Full Text] [Related]
3. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
4. Association of Decreased Expression of Serum miR-9 with Poor Prognosis of Oral Squamous Cell Carcinoma Patients.
Sun L; Liu L; Fu H; Wang Q; Shi Y
Med Sci Monit; 2016 Jan; 22():289-94. PubMed ID: 26813876
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma.
Xu H; Yang Y; Zhao H; Yang X; Luo Y; Ren Y; Liu W; Li N
Tumour Biol; 2016 Jan; 37(1):447-53. PubMed ID: 26224475
[TBL] [Abstract][Full Text] [Related]
6. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
[TBL] [Abstract][Full Text] [Related]
7. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
8. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of miR-187 modulates the advances of oral carcinoma by targeting BARX2 tumor suppressor.
Lin SC; Kao SY; Chang JC; Liu YC; Yu EH; Tseng SH; Liu CJ; Chang KW
Oncotarget; 2016 Sep; 7(38):61355-61365. PubMed ID: 27542258
[TBL] [Abstract][Full Text] [Related]
10. Tumor expression of miR-448 is a prognostic marker in oral squamous cell carcinoma.
Wei H; Yu K; Liu Y; Li L; Wang G
BMC Cancer; 2020 Aug; 20(1):756. PubMed ID: 32787801
[TBL] [Abstract][Full Text] [Related]
11. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
12. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
[TBL] [Abstract][Full Text] [Related]
13. AURKA is a predictor of chemotherapy response and prognosis for patients with advanced oral squamous cell carcinoma.
Li Y; Zhang J
Tumour Biol; 2015 May; 36(5):3557-64. PubMed ID: 25547434
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by
Soltaninezhad P; Arab F; Mohtasham N; FakherBaheri M; Kavishahi NN; Aghaee-Bakhtiari SH; Zare-Mahmoodabadi R; Pakfetrat A; Taban KI; Mohajertehran F
Curr Pharm Des; 2024; 30(4):310-322. PubMed ID: 38310566
[TBL] [Abstract][Full Text] [Related]
15. Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients.
Yan Y; Wang X; Venø MT; Bakholdt V; Sørensen JA; Krogdahl A; Sun Z; Gao S; Kjems J
Oncotarget; 2017 Jan; 8(5):8206-8214. PubMed ID: 28030794
[TBL] [Abstract][Full Text] [Related]
16. Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma.
Singh P; Srivastava AN; Sharma R; Mateen S; Shukla B; Singh A; Chandel S
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1053-1057. PubMed ID: 29699056
[TBL] [Abstract][Full Text] [Related]
17. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-92b promotes tumor growth and activation of NF-κB signaling via regulation of NLK in oral squamous cell carcinoma.
Liu Z; Diep C; Mao T; Huang L; Merrill R; Zhang Z; Peng Y
Oncol Rep; 2015 Dec; 34(6):2961-8. PubMed ID: 26503628
[TBL] [Abstract][Full Text] [Related]
19. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
20. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
